USPTO 2015–2025 USPTO PatentsView Foreign Corporation

Seqirus UK Limited

USPTO PatentsView assignee record - 35 granted patents across 9 technology areas, recorded in grant years 2016–2025. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA).

35
Total patents granted
9
CPC technology areas
18.9
Avg claims per patent
-21%
5-year grant velocity

The verdict

According to USPTO PatentsView, Seqirus ranks #9,120 of 50,000 tracked US assignees by granted-patent volume, with 35 patents across 9 technology areas.

#9,120
of 50,000 US assignees by volume
Top 41%
by Innovation Score (38.4/100)
18.9
avg claims per patent
-21%
grant velocity, last 5 yrs

Portfolio overview

Seqirus UK Limited has been granted 35 US utility patents between 2016 and 2025, placing Seqirus UK Limited at #9,120 of 50,000 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 18.9 claims per patent with primary concentration in C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA). As a Foreign Corporation, Seqirus UK Limited is one of the more focused assignees in the PatentsView dataset. By volume, Seqirus sits between Ssenstone Inc. (35 patents, rank #9,121) and Soreq Nuclear Research Center (35 patents, rank #9,129) - the closest US assignees by grant volume. The composite Innovation Score of 38.4/100 blends portfolio volume, grant velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.

Grant cadence records the difference between two grant-year windows. Between 2020 and 2024 the company received 15 grants, compared with 19 in the 2015–2019 window, a -21% shift in five-year grant velocity. Both windows cover five complete grant years; the latest PatentsView year is a partial release and is excluded from this comparison, though it still appears in the yearly table and chart below. Grant timing can lag the related application by years, so this comparison does not establish current R&D spending, strategic intent, or a company’s application activity. The Foreign Corporation classification provides context for the assignee record, not a conclusion about its business strategy.

Claim depth and technology breadth describe this aggregate record. Seqirus UK Limited's 18.9 average claims per patent is an average count, not a measure of claim scope, legal strength, enforceability, or design-around risk. The record spans 9 CPC subclasses. Combined with portfolio volume, these figures let readers compare the documented grant records of assignees in similar technology classes.

Who files at Seqirus's volume?

Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀

patents

What this shows Seqirus holds 35 patents at rank #9,125, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.

Source USPTO PatentsView, granted utility patents As of 2015–2025

Companies ranked near Seqirus

By rank, the assignees closest to #9,125 in granted patent volume.

Leaders in C12N (Microorganisms OR Enzymes)

Other assignees with the most granted patents in Seqirus's primary technology class.

Assignees with similar portfolio profiles

Two PlainPatent-derived peer sets for Seqirus, neither rank-band nor same-CPC leaders (those blocks stay above).

Seqirus's Innovation Score vs. every tracked assignee

Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)

38 Top 41% higher than 59% of 50,000 US assignees

0–10: 687 US assignees (1%). Below this entry. 10–20: 2,527 US assignees (5%). Below this entry. 20–30: 13,162 US assignees (26%). Below this entry. 30–40: 15,294 US assignees (31%). This entry sits in this band. 40–50: 11,491 US assignees (23%). Above this entry. 50–60: 5,058 US assignees (10%). Above this entry. 60–70: 1,537 US assignees (3%). Above this entry. 70–80: 234 US assignees (0%). Above this entry. 80–90: 10 US assignees (0%). Above this entry. 90–100: 0 US assignees (0%). Above this entry. This assignee 0 100 every tracked assignee, bucketed by value

Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.

Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025

02468 2016201720182019202020212022202320242025 1
USPTO utility patent grants by year · 2016–2025

Grants by year

Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.

View data table
Seqirus UK Limited patent grants by year, 2015–2025
Year Patents Granted Share of Period
2016 2 5.7%
2017 7 20.0%
2018 4 11.4%
2019 6 17.1%
2020 5 14.3%
2021 2 5.7%
2022 4 11.4%
2023 1 2.9%
2024 3 8.6%
2025partial year 1 2.9%

Grant record at a glance

Portfolio Volume 35 grants
CPC subclasses 9
Avg. claims / grant 18.9
Velocity -21%

Historical grant data only; it does not rate legal strength or current strategy.

Where it ranks

Overall rank by patents

#9,120

of 50,000 tracked assignees

Innovation Score

38.4 out of 100

View all rankings →

Data Source

USPTO PatentsView, US granted patents 2015–2025

How is Innovation Score calculated?

Frequently Asked Questions

Where does Seqirus UK Limited rank among US patent assignees?
According to USPTO PatentsView (2015–2025 granted utility patents), Seqirus UK Limited ranks #9,120 of 50,000 assignees by granted-patent volume, the same sort as the companies listing and top-holders ranking. See /methodology/#corpus-placement.
How many patents does Seqirus UK Limited hold?
Seqirus UK Limited holds 35 US utility patents granted between 2016 and 2025, spanning 9 technology areas.
What is Seqirus UK Limited's Innovation Score?
Seqirus UK Limited has an Innovation Score of 38.4 out of 100 (top 41% of the corpus). This composite metric weighs portfolio volume (40%), grant velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Seqirus UK Limited focus on?
Seqirus UK Limited's top technology area is C12N (MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA) with 35 patents. Grants appear in 9 CPC subclasses total.
Is Seqirus UK Limited's patent grant rate increasing or decreasing?
Seqirus UK Limited's recent grant velocity is -21% compared to the prior five-year period (grant years, not application filing dates). Grant activity has slowed relative to earlier years.
What does claim depth mean for Seqirus UK Limited's patents?
Seqirus UK Limited's patents average 18.9 claims each. This is an aggregate descriptive count from the grant record; it does not establish claim scope, legal strength, enforceability, or design-around risk.
How is the Seqirus UK Limited patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.

How to use this portfolio

Seqirus's 35 grants land it in the top 41% by Innovation Score, but volume alone doesn't tell you where the strength sits.

  • Read that count against the largest US assignees before treating it as dominance - Seqirus ranks #9,120 of 50,000. Top 50 holders
  • Most of this portfolio concentrates in C12N - see who else leads that technology area. C12N leaders
  • Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works

Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.

Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.